These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 17193223)
1. Synthesis and biological evaluation of new quinazoline and cinnoline derivatives as potential atypical antipsychotics. Alvarado M; Barceló M; Carro L; Masaguer CF; Raviña E Chem Biodivers; 2006 Jan; 3(1):106-17. PubMed ID: 17193223 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus. Fiorino F; Severino B; De Angelis F; Perissutti E; Magli E; Frecentese F; Esposito A; Massarelli P; Nencini C; Viti B; Santagada V; Caliendo G Pharmazie; 2009 Sep; 64(9):555-64. PubMed ID: 19827295 [TBL] [Abstract][Full Text] [Related]
12. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789 [TBL] [Abstract][Full Text] [Related]
13. 1-cinnamyl-4-(2-methoxyphenyl)piperazines: synthesis, binding properties, and docking to dopamine (D(2)) and serotonin (5-HT(1A)) receptors. Penjisević J; Sukalović V; Andrić D; Kostić-Rajacić S; Soskić V; Roglić G Arch Pharm (Weinheim); 2007 Sep; 340(9):456-65. PubMed ID: 17763374 [TBL] [Abstract][Full Text] [Related]
14. 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). Bolós J; Anglada L; Gubert S; Planas JM; Agut J; Príncep M; De la Fuente N; Sacristán A; Ortiz JA J Med Chem; 1998 Dec; 41(27):5402-9. PubMed ID: 9876110 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656 [TBL] [Abstract][Full Text] [Related]
16. Studies towards the identification of a new generation of atypical antipsychotic agents. Garzya V; Forbes IT; Gribble AD; Hadley MS; Lightfoot AP; Payne AH; Smith AB; Douglas SE; Cooper DG; Stansfield IG; Meeson M; Dodds EE; Jones DN; Wood M; Reavill C; Scorer CA; Worby A; Riley G; Eddershaw P; Ioannou C; Donati D; Hagan JJ; Ratti EA Bioorg Med Chem Lett; 2007 Jan; 17(2):400-5. PubMed ID: 17084080 [TBL] [Abstract][Full Text] [Related]
17. Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis. Hamacher A; Weigt M; Wiese M; Hoefgen B; Lehmann J; Kassack MU BMC Pharmacol; 2006 Sep; 6():11. PubMed ID: 16978403 [TBL] [Abstract][Full Text] [Related]
18. Chemoenzymatic synthesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics. Caro Y; Torrado M; Masaguer CF; Raviña E; Padín F; Brea J; Loza MI Bioorg Med Chem Lett; 2004 Feb; 14(3):585-9. PubMed ID: 14741248 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands. Ortega R; Raviña E; Masaguer CF; Areias F; Brea J; Loza MI; López L; Selent J; Pastor M; Sanz F Bioorg Med Chem Lett; 2009 Mar; 19(6):1773-8. PubMed ID: 19217777 [TBL] [Abstract][Full Text] [Related]